報價延遲最少15分鐘:2026/04/22 03:00 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2575 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.44/0.05
|
|
企業價值
136.99M
|
| 資產負債 |
|
每股賬面淨值
-0.03
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
39.55M
|
|
每股收益
0.49
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Sangamo Therapeutics Inc is a genomic medicine company committed to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases. Its neurology development is focused on two areas: development of epigenetic regulation therapies to treat serious neurological diseases and development of novel engineered adeno-associated virus, or AAV, capsids to deliver its therapies to the intended neurological targets. The group's pipeline products are Small Fiber Neuropathy, Prion Disease, Tauopathies, ALS/FTD, Huntington's Disease, Fabry Disease, and Hemophilia A. |
